UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (430) 430
life sciences & biomedicine (389) 389
humans (383) 383
agammaglobulinaemia tyrosine kinase (370) 370
animals (272) 272
mice (187) 187
protein-tyrosine kinases - genetics (182) 182
protein-tyrosine kinases - metabolism (169) 169
male (151) 151
immunology (134) 134
bruton's tyrosine kinase (119) 119
signal transduction (107) 107
hemic and lymphatic diseases (106) 106
female (103) 103
agammaglobulinemia - genetics (100) 100
mutation (93) 93
tyrosine (93) 93
biochemistry & molecular biology (90) 90
agammaglobulinaemia tyrosine kinase - antagonists & inhibitors (84) 84
protein-tyrosine kinases - antagonists & inhibitors (81) 81
hematology (76) 76
abridged index medicus (74) 74
phosphorylation (71) 71
protein-tyrosine kinase (69) 69
x chromosome (69) 69
oncology (68) 68
molecular sequence data (66) 66
protein-tyrosine kinases - physiology (64) 64
adult (62) 62
b-lymphocytes - immunology (61) 61
protein kinase inhibitors - therapeutic use (58) 58
agammaglobulinaemia tyrosine kinase - metabolism (57) 57
immune system diseases (57) 57
mice, inbred c57bl (57) 57
leukemia, lymphocytic, chronic, b-cell - drug therapy (56) 56
pyrimidines - therapeutic use (56) 56
btk (52) 52
protein kinase inhibitors - pharmacology (52) 52
pyrazoles - therapeutic use (52) 52
cell biology (51) 51
kinases (49) 49
cell line (48) 48
pyrimidines - pharmacology (48) 48
amino acid sequence (45) 45
b-lymphocytes - metabolism (45) 45
base sequence (45) 45
genetic linkage (45) 45
middle aged (45) 45
b-lymphocytes - enzymology (44) 44
aged (43) 43
receptors, antigen, b-cell - metabolism (43) 43
mice, knockout (42) 42
protein-tyrosine kinases - chemistry (42) 42
protein-tyrosine kinases - deficiency (42) 42
enzyme activation (40) 40
pyrazoles - pharmacology (40) 40
agammaglobulinaemia tyrosine kinase - genetics (39) 39
cells, cultured (39) 39
leukemia (39) 39
research (38) 38
multidisciplinary sciences (37) 37
proteins (37) 37
science & technology - other topics (37) 37
agammaglobulinemia (36) 36
lymphocytes b (36) 36
ibrutinib (35) 35
agammaglobulinemia - immunology (33) 33
lymphoma (33) 33
mice, inbred cba (33) 33
b cells (32) 32
immunodeficiency (32) 32
treatment outcome (32) 32
cell line, tumor (31) 31
protein kinase inhibitors - adverse effects (30) 30
research article (30) 30
x-linked agammaglobulinemia (30) 30
analysis (29) 29
child (29) 29
flow cytometry (29) 29
pyrimidines - adverse effects (29) 29
x-linked agammaglobulinaemia (29) 29
antineoplastic agents - pharmacology (28) 28
point mutation (28) 28
protein tyrosine kinase (28) 28
pyrimidines - administration & dosage (28) 28
signal transduction - drug effects (28) 28
signal transduction - immunology (28) 28
agammaglobulinemia - enzymology (27) 27
bruton’s tyrosine kinase (27) 27
cell differentiation (27) 27
pyrazoles - adverse effects (27) 27
apoptosis (26) 26
child, preschool (26) 26
lymphocyte activation (26) 26
b-lymphocytes - cytology (25) 25
care and treatment (25) 25
lymphoma, mantle-cell - drug therapy (25) 25
health aspects (24) 24
protein kinase inhibitors - administration & dosage (24) 24
receptors, antigen, b-cell - physiology (24) 24
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Leukemia, ISSN 0887-6924, 10/2017, Volume 31, Issue 10, pp. 2075 - 2084
...]] Ibrutinib is a covalent, irreversible inhibitor of Bruton's tyrosine kinase, a key BCR protein.[sup.[2]] It was approved for the treatment of CLL based on its excellent... 
Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Peptide Fragments | Pyrazoles - therapeutic use | Proto-Oncogene Proteins c-bcl-2 - physiology | Apoptosis - drug effects | Humans | Neoplasm Proteins - physiology | Pyrazines - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - agonists | Neoplasm Proteins - antagonists & inhibitors | Pyrazines - therapeutic use | Molecular Targeted Therapy | Benzamides - administration & dosage | Benzamides - therapeutic use | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Sulfonamides - agonists | Benzamides - pharmacology | Proto-Oncogene Proteins | Pyrazoles - pharmacology | Pyrimidines - administration & dosage | Bcl-2-Like Protein 11 - genetics | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Clinical Trials as Topic | Mitochondria - drug effects | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Bcl-2-Like Protein 11 - biosynthesis | Drug Synergism | Protein Kinase Inhibitors - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Pyrazoles - administration & dosage | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Agammaglobulinaemia Tyrosine Kinase | Protein Kinase Inhibitors - pharmacology | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Pyrazines - pharmacology | Sulfonamides - administration & dosage | Drug Resistance, Neoplasm - drug effects | Drug Screening Assays, Antitumor | Protein-Tyrosine Kinases - antagonists & inhibitors | Enzymes | Chronic lymphocytic leukemia | Care and treatment | Development and progression | Genetic aspects | Regulation | Drug resistance | Health aspects | Killing | Tyrosine | Drugs | Medical research | Chronic lymphatic leukemia | Bcl-2 protein | Leukemia | Clinical trials | Priming | Lymphatic leukemia | Patients | Bruton's tyrosine kinase | Mitochondria | Inhibitors | Cell death | Sensitivity enhancement | Inhibition | Pretreatment | Protein-tyrosine kinase | BIM protein | Apoptosis | Index Medicus | ibrutinib | BCL-2 | mitochondrial priming | acalabrutinib (ACP-196) | BTK | venetoclax | BH3 profiling
Journal Article
Journal Article
Cancer discovery, ISSN 2159-8290, 09/2017, Volume 7, Issue 9, pp. 1018 - 1029
Journal Article
Journal Article
Journal Article
Molecular cancer, ISSN 1476-4598, 02/2018, Volume 17, Issue 1, pp. 57 - 57
textabstractBruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic signaling that is critical for proliferation and survival of leukemic cells in many B cell malignancies... 
Chronic lymphocytic leukemia | Tumor microenvironment | B cell receptor signaling | Leukemia | Chemokine receptor | B cell development | Bruton's tyrosine kinase | Lymphoma | Ibrutinib | Biochemistry & Molecular Biology | Oncology | Life Sciences & Biomedicine | Science & Technology | Leukemia, B-Cell - metabolism | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Tumor Microenvironment | Leukemia, B-Cell - etiology | Receptors, Antigen, B-Cell - metabolism | Molecular Targeted Therapy | Biomarkers, Tumor | Cell Differentiation - genetics | Agammaglobulinaemia Tyrosine Kinase - metabolism | Cell Transformation, Neoplastic - genetics | Leukemia, B-Cell - drug therapy | Agammaglobulinaemia Tyrosine Kinase - chemistry | B-Lymphocytes - pathology | Gene Expression Regulation, Neoplastic - drug effects | Lymphoma, B-Cell - etiology | Bone Marrow | B-Lymphocytes - metabolism | Lymphoma, B-Cell - drug therapy | Lymphoma, B-Cell - metabolism | Lymphopoiesis - ethics | Leukemia, B-Cell - pathology | Treatment Outcome | Cell Transformation, Neoplastic - metabolism | Animals | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Lymphoma, B-Cell - pathology | Agammaglobulinaemia Tyrosine Kinase - genetics | Protein Kinase Inhibitors - pharmacology | Care and treatment | Usage | Lymphomas | Research | Chemokines | Cancer | Index Medicus | Bruton’s tyrosine kinase
Journal Article
PloS one, ISSN 1932-6203, 07/2016, Volume 11, Issue 7, pp. e0159607 - e0159607
Acalabrutinib (ACP-196) is a second-generation inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK... 
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Lethargy - physiopathology | Protein-Tyrosine Kinases - metabolism | Diarrhea - physiopathology | Humans | Pyrazines - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Weight Loss - drug effects | Diarrhea - chemically induced | Anorexia - physiopathology | Benzamides - administration & dosage | Protein-Tyrosine Kinases - genetics | Antineoplastic Agents - adverse effects | Female | B-Lymphocytes - pathology | Drug Evaluation, Preclinical | Benzamides - adverse effects | Disease Models, Animal | Lymphoma, Large B-Cell, Diffuse - drug therapy | Drug Administration Schedule | Lymphoma, Large B-Cell, Diffuse - enzymology | Lethargy - chemically induced | Lymphoma, Large B-Cell, Diffuse - mortality | B-Lymphocytes - drug effects | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Vomiting - chemically induced | Animals | B-Lymphocytes - immunology | Agammaglobulinaemia Tyrosine Kinase | Dogs | Pyrazines - adverse effects | Cell Line, Tumor | Anorexia - chemically induced | Lymphoma, Large B-Cell, Diffuse - veterinary | Vomiting - physiopathology | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Care and treatment | Safety and security measures | Dosage and administration | Non-Hodgkin's lymphomas | Research | Antineoplastic agents | Cell proliferation | Cell culture | Flow cytometry | Veterinary colleges | Anorexia | Leukemia | Cytotoxicity | Malignancy | Kinases | Veterinary medicine | Vomiting | Quality | Inhibition | Protein-tyrosine kinase | Tyrosine | Internal medicine | Hematology | Agammaglobulinemia | Diarrhea | Gene expression | Lymphoma | Bruton's tyrosine kinase | Inhibitors | Lymphocytes B | Lethargy | Cancer | B-cell lymphoma | Index Medicus | Lymphomas
Journal Article